🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. DEXAMETHASONE , ENFORTUMAB VEDOTIN , -, PARACETAMOL , -, MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  2. DT-168

    Lxo Ireland Designated Activity Company

    Fuchs Endothelial Corneal Dystrophy

    phase 2 small molecule active

    1 trial

  3. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  4. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  6. Degarelix

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  7. Dexmedetomidine sublingual film

    BioXcel Therapeutics

    Delirium

    phase 2 small molecule terminated

    1 trial

  8. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  9. Donanemab

    Eli Lilly and Company

    Cognitive Dysfunction

    phase 2 small molecule active

    1 trial

  10. ELACESTRANT

    Fondazione Telethon ETS

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    phase 2 small molecule active

    1 trial

  11. ELI-002 7P

    Elicio Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  13. ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  14. ER004

    Pierre Fabre Medicament

    X-linked hypohidrotic ectodermal dysplasia (XLHED)

    phase 2 small molecule active

    1 trial

  15. Efgartigimod, ARGX-113

    argenx

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  16. Elironrasib

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  17. Elotuzumab, Selinexor, and Dexamethasone (ESd)

    Karyopharm Therapeutics Inc

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  18. Eltrekibart

    Eli Lilly and Company

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  19. Eltrekibart, 0.9% sodium chloride

    Eli Lilly Co.

    Moderate to Severe Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  20. Eltrekibart, 0.9% sodium chloride, Mirikizumab, Mirikizumab, Placebo for LY3074828 SC Injection, 1mL Prefilled Syringe

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  21. Enfortumab vedotin

    United Therapeutics Europe Ltd

    Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  22. Erdafitinib Intravesical Delivery System

    Janssen Cilag International NV

    Non-Muscle Invasive Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  23. Etrumadenant, Quemliclustat, FLUOROURACIL, BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, Zimberelimab, Etrumadenant, REGORAFENIB

    Arcus Biosciences

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  24. Experimental: tislelizumab+anlotinib

    The First People's Hospital of Lianyungang

    Thymic Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources